Nutrition Insight writes…
The Association for the Cannabinoid Industry (ACI) has positively responded to the UK Home Office’s call to create a legal framework for consumer CBD products that contain controlled cannabinoids, accepting expert recommendations. The government had not responded to these prior.
“It is imperative for the nascent UK consumer cannabinoid sector that a legal framework is put in place to provide comfort for companies operating in the space and reassurance for consumers and retailers,” says Steve Moore, co-founder of the ACI.
“This will also help accelerate the regulatory process that businesses have invested in. It only adds to the importance of the explicit commitment to bring forward the necessary amendments to the Misuse of Drugs 2001 regulations.”
The ACI will comment further after meetings in the coming days with senior Home Office officials who have engaged with this issue in the past three months.
CBD clarification
In 2021, Kit Malthouse, the then minister of state for crime and policing, acknowledged the need for legal clarification. “There is currently no legal framework in place specifically exempting CBD products from control under the Misuse of Drugs Act 1971.”
“With this in mind, the government wishes to explore the possibility of creating a specific exemption in the Misuse of Drugs Regulations 2001 (‘the 2001 Regulations’) for CBD products which contain no more than a defined trace percentage of controlled cannabinoids,” says Malthouse.The UK government has accepted recommendations to create a legal framework for CBD products in the UK.
The government proposals came after ACI launched a “Save our CBD” campaign earlier this year urging the Home Office to update the law. The premise of the campaign insisted that without a legal framework the growing market for CBD products in the UK would be stifled. At the time, the campaigners said the uncertainty in the industry puts 400 CBD suppliers in jeopardy of closure.
Furthermore, the ACI and the Centre for Medicinal Cannabis partnered with Chem ID to improve the authenticity and quality of commercial cannabis extract and medical cannabis markets in the UK and Europe.
Read the full report at
